NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting

NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting
SAN CARLOS, Calif., May 20 /PRNewswire-FirstCall/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track [...]

New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of …

New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of …
LUND, SWEDEN–(Marketwire – 04/15/10) – – Enhanced levels of brain derived neurotrophic factor, possibly contributing to neuroprotection, were shown in laquinimod treated multiple sclerosis (MS) patients – Laquinimod significantly reduce demyelination and axonal damage as shown in animal models [...]